RANOLAZINE IN ISCHEMIC HEART DISEASE

Abstract

Study results of a new anti-anginal drug (an inhibitor of sodium channels — ranolazine) are presented. Indications, contraindications, major clinical trials of the drug in patients with ischemic heart disease are considered.

Keywords

• ишемическая болезнь сердца
• стенокардия
• острый коронарный синдром
• медикаментозное лечение
• ранолазин